HighTower Advisors LLC Buys 1,944 Shares of Regeneron Pharmaceuticals, Inc. $REGN

HighTower Advisors LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.4% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,731 shares of the biopharmaceutical company’s stock after acquiring an additional 1,944 shares during the period. HighTower Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $25,715,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of REGN. Osaic Holdings Inc. boosted its position in Regeneron Pharmaceuticals by 55.2% during the 2nd quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock worth $9,607,000 after buying an additional 6,073 shares during the period. Robeco Institutional Asset Management B.V. boosted its position in shares of Regeneron Pharmaceuticals by 153.4% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock worth $67,969,000 after purchasing an additional 73,176 shares in the last quarter. PGGM Investments raised its position in shares of Regeneron Pharmaceuticals by 9.7% during the third quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company’s stock worth $52,057,000 after purchasing an additional 8,187 shares during the period. Rakuten Investment Management Inc. bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $33,121,000. Finally, Simplify Asset Management Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 34.0% during the second quarter. Simplify Asset Management Inc. now owns 3,697 shares of the biopharmaceutical company’s stock valued at $1,941,000 after buying an additional 939 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Insider Activity

In related news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the sale, the director directly owned 17,803 shares in the company, valued at approximately $13,860,169.59. The trade was a 0.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,636 shares of company stock worth $2,862,920 in the last quarter. 7.02% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on REGN. Cantor Fitzgerald boosted their price target on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a report on Monday, February 2nd. Scotiabank increased their price target on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research report on Monday, November 24th. Wall Street Zen cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday. Finally, Canaccord Genuity Group upped their price objective on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $793.81.

Regeneron Pharmaceuticals Stock Down 0.2%

Shares of Regeneron Pharmaceuticals stock opened at $792.16 on Thursday. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The company has a market cap of $83.75 billion, a P/E ratio of 19.06, a PEG ratio of 2.13 and a beta of 0.40. The company’s fifty day simple moving average is $767.50 and its two-hundred day simple moving average is $670.90.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the previous year, the firm posted $12.07 EPS. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be given a $0.94 dividend. The ex-dividend date of this dividend is Friday, February 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.47%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.